b'Management of Asymptomatic\nRenal Stones in Astronauts\n\nFor the NASA HRP Investigator\xe2\x80\x99s Workshop\nDavid Reyes & James Locke\nGalveston, Texas\nFebruary 2016\n\nOverview\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\nThe problem of small asymptomatic stones\nBackground and risks\nHistorical data\nHow to screen for small stones\nTreatment and waiver\n\nSmall and Asymptomatic\n\xe2\x80\xa2 Small calcifications difficult to detect\n\xe2\x80\xa2 What is their significance?\n\xe2\x80\xa2 Parenchymal or in the collecting system\n\xe2\x80\xa2 Stable or growing\n\xe2\x80\xa2 Treat asymptomatic ditzels?\n\xe2\x80\xa2 Or Leave them there?\n\xe2\x80\xa2 How to monitor over time?\n\nNatural History\nSize (mm) Stone Free Progression\n\nIntervention\n\n<= 5\n\n28%\n\n40.4%\n\n5.3%\n\n5 - 10\n\n4.8%\n\n52.4%\n\n9.5%\n\n>= 10\n\n0%\n\n71.4%\n\n14.3%\n\nKoh, et al. (2011), Outcomes of long-term follow-up of patients with conservative\nmanagement of asymptomatic renal caliculi, BJU Int, 109:622-625.\n\nSpontaneous Passage versus Stone Size\n(Ueno, et al. (1977), Relation of spontaneous passage of ureteral calculi to size, Urology, 10(6):544-546.)\n\nGeneral Population\n\xe2\x80\xa2\n\nLifetime prevalence 10% male, 5% female\n\n\xe2\x80\xa2\n\nIncreasing incidence (20 - 74 y.o.)\n\n\xe2\x80\xa2\n\n3.2% to 5.2% (+ male)\n\n\xe2\x80\xa2\n\n3.7 % to 4.6% of commercial aviation\n2\npilots between 2000 \xe2\x80\x93 2007\n\n1. Hall, P. (2009) Nephrolithiasis: Treatment, causes and prevention, Clev Clin J Med, 76(10):583-591\n2. Hyams, E., et al. (2011) The incidence of urolithiasis among commercial aviation pilots, J Uro, 186:914-916.\n\nIMM Renal Stone Risk\nProbability (%)\nDRM\n\nNo\nEvents\n\nAny\nEvent\n\nBest\nCase\n\nWorst\nCase\n\nLunar\n\n99.979\n\n0.021\n\n0.013\n\n0.003\n\n99.818\n\n0.182\n\n0.110\n\n0.072\n\n99.092\n\n1.090\n\n0.659\n\n0.430\n\n(21 Days)\n\nISS\n(6 months)\n\nMars\n(3 years)\n\nIMM Data Request #: D-20150911-334\n\nLSAH / EMR Review,\n\nApril 2014\n\n\xe2\x80\xa2At least 19 astronauts affected\n\xe2\x80\xa23 females, 16 males\n\xe2\x80\xa2Treatment and prevention varied\n\n\xe2\x80\xa2Monitoring parameters varied\n\nLSAH Review,\n# of Events\n\nJuly 2015\n\nLong\nDuration\n\nShort\nDuration\n\nPreflight\n\n4\n\nR+0-90 days\n\n1\n\n1\n\nR+90-180 days\n\n3\n\n1\n\nR+180-270 days\n\n1\n\n1\n\nR+270-365 days\n\n2\n\n2\n\nInter-flight\n\n4\n\nR>365 days\n\n21\n\nGrand Total\n\n36\n\n1\n\n2\n\n3\n21\n\n3\n\n29\n\nHow to Screen?\n\xe2\x80\xa2\n\xe2\x80\xa2\n\n\xe2\x80\xa2\n\xe2\x80\xa2\n\n\xe2\x80\xa2\n\nLanguage matters\n\xe2\x80\xa2 Mineralized renal material or stone?\nUltrasound!\n\xe2\x80\xa2 No radiation\n\xe2\x80\xa2 Almost as good as CT\nCT for possible stones\nFlexible Ureteroscopy\n\xe2\x80\xa2 Both diagnosis and treatment\nWhat use are urine studies?\n\nSensitivity (%)\n\nSpecificity (%)\n\nDose (mSv)\n\nUltrasound\nAverage 2.6mm (1 \xe2\x80\x93 9 mm, SD 1.15), n=51 pts, 114 stones [17]\nShadowing alone\n\n65 (PPV 90)\n\n-\n\n0\n\nTwinkling alone\n\n81 (PPV 94)\n\n-\n\n0\n\nShadowing + Twinkle\n\n88 (PPV 96)\n\n-\n\n0\n\nAverage 3.9mm ( 1-20 mm), n=105 pts, 65 stones, CT as reference [18]\nShadowing alone\n\n48 (PPV 81)\n\n99\n\n0\n\nShadowing + Twinkle\n\n55 (PPV 67)\n\n99\n\n0\n\n45 - 58\n85\n\n69 - 77\n90\n\n0.7\n3\n\n97\n\n95\n\n3\n\n95 \xe2\x80\x93 98\n\n96 - 98\n\n10\n\nX-Ray\n\nKUB\nIVP\nCT\nLow-dose, non-con.\nNon-contrast\nMRI\n\n93 - 100\n\n95 - 100\n\n0\n\nWhen to Screen?\n\nEnhanced U/S Protocol\n1.\n\nEchogenic \xef\x83\xa0 seen\n\n2.\n\nTwinkling \xef\x83\xa0 frequency\n\n3.\n\nShadowing \xef\x83\xa0 opaque\n\n4.\n\nLocalizable \xef\x83\xa0 papilla/collecting\n\n5.\n\nMeasurable \xef\x83\xa0\n\nfrom 2 or more angles\ndispersion / \xe2\x80\x9ctwinkling\xe2\x80\x9d\n\nto ultrasound\n\n>= 3 mm\n\nsystem\n\nClinical Practice Guideline\n\xe2\x80\xa2\n\nUse of specialized ultrasound protocol\n\n\xe2\x80\xa2\n\nYearly ultrasound for all astronauts??\n\n\xe2\x80\xa2\n\nMRM by ultrasound may require\xe2\x80\xa6\n\xe2\x80\xa2\n\n\xe2\x80\xa2\n\nLow-dose, high resolution CT\n\nMRM by CT\xe2\x80\xa6\n\xe2\x80\xa2\n\nthen Flexible Ureteroscopy??\n\n\xe2\x80\xa2\n\nMission assignment affects treatment method\n\n\xe2\x80\xa2\n\nPotential waivers for very small, stable MRM\n\nUS Navy Standards\n\xe2\x80\xa2\n\nWaivers given for...\n\xe2\x80\xa2 calcium oxalate, calcium phosphate, uric acid\nand struvite;\n\xe2\x80\xa2 retained stones in the renal parenchyma;\n\xe2\x80\xa2 recurrent stones > 12 months apart.\n\n\xe2\x80\xa2\n\nMedical evaluation & urology consult required\n\nUS Navy Standards\n\xe2\x80\xa2\n\nWaivers NOT given for...\n\xe2\x80\xa2 recurrent stones within one year,\n\xe2\x80\xa2 cysteine stones,\n\xe2\x80\xa2 hypercalcuria,\n\xe2\x80\xa2 stones retained in the collecting system.\n\nExploration Missions?\n\nUreteral Stone Size and Time to Passage\nMiller and Kane (1999), Time to stone passage for observed ureteral calculi: A guide for patient education,\nJ. Urology, 162:688-691.\n\nBack-Up\n\nIMM \xe2\x80\x93 Renal Stone Events\n\nProbability Per Mission of One or More Event (%)\nDRM**\n\nAny Event (95% CI)\n\nBest Case (95% CI)\n\nWorst Case (95%)\n\n0.003 (0.0033 \xe2\x80\x93\n\nLunar (21 day)\n0.021 (0.017 \xe2\x80\x93 0.026) 0.0127 (0.0074 \xe2\x80\x93 0.019)\n\n0.014)\n0.072 (0.029 \xe2\x80\x93\n\nISS (6 month)\n0.182 (0.149 \xe2\x80\x93 0.222)\n\n0.110 (0.064 \xe2\x80\x93 0.165)\n0.122)\n0.430 (0.172 \xe2\x80\x93\n\nMars (3 year)\n1.090 (0.887 \xe2\x80\x93 1.320)\n\n0.659 (0.383 \xe2\x80\x93 0.986)\n0.730)\n\nWatch and Wait*\nApplication\n\nStone Free\n\nbest for renal\nor ureteral <5 mm // 28%\nstones <5 mm\n\nPros\n\nCons\n\ndo no harm\n\ntime, stone\ngrowth (50%)\n\nKoh, et al. (2011), Outcomes of long-term follow-up of patients with conservative\nmanagement of asymptomatic renal calculi, BJU Int, 109:622-625.\n\nMedical Expulsive Therapy\nApplication\n\nStone Free\n\nPros\n\nCons\n\nbest for distal\nureteral\nstones\n\n<4 mm //\n55%\n\na bit better\nthan waiting\n\nneed for\ntreatment\n\nMoe, et al. (2011), Pharmacotherapy of urolithiasis: evidence from clinical\ntrials, Kidney Intl., 79:385-392.\n\nLithotripsy (ESWL)\nApplication\n\nStone Free\n\n23 - 82% depend\nbest for renal\non size and\nstones 10-20\nlocation, better\nmm\nw/ MET\n\nPros\n\nCons\n\nnoninvasive,\nwidely\navailable\n\nRadiation, no\nbetter for\nsmall stones,\nretained frags\n\nObek, et al., (2001), The efficacy of extracorporeal\nshock wave lithotripsy for isolated lower pole calculi\ncompared with isolated middle and upper caliceal\ncalculi, J Urol, 166:2081-2085.\nImages from: www.kidneystoners.org\n\nFlexible Ureteroscopy**\nApplication\n\nCan be used\nfor any stone\n\nStone\nFree\n\n>90%\n\nPros\n\nCons\n\nhigh-stone\nfree rate, low\nretreat rate\n\nless widely\navailable,\noperator\ndependent\n\nHussain, et al. (2011),\nRedefining the limits of flexible\nureterorenoscopy, J Endourol,\n25(1):45-49.\nImages from: www.kidneystoners.org\n\nNephrostomy\nApplication\nlarge,\ncomplicated,\nstaghorn, other\n\nStone Free\n\n>95%\n\nPros\n\nCons\n\ndefinitive\ntreatment\n\ninvasive,\nserious\ncomplications\npossible\n\nBreda, et al. (2011), Flexible\nuretroscopy and laser lithotripsy for\nsingle intrarenal stones 2 cm or\ngreater - is this the new frontier?, J\nUrol, 179:981-984\nImages from: www.kidneystoners.org\n\n'